Potential avenues for immunotherapy of colitis-associated neoplasia

Immunotherapy

Volumn 4, Issue 4, 2012, Pages 397-405

  Waldner, Maximilian J ^a   Neurath, Markus F ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

colorectal cancer; Crohn's disease; cytokines; IL 6; inflammation; inflammatory bowel diseases; STAT3; TNF ; ulcerative colitis

Indexed keywords

FAS ASSOCIATED DEATH DOMAIN PROTEIN; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 17; INTERLEUKIN 6; PROSTAGLANDIN SYNTHASE; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN RECEPTOR 2; WNT PROTEIN;

ANGIOGENESIS; APOPTOSIS; B LYMPHOCYTE; CANCER GROWTH; CANCER INVASION; CANCER RISK; CANCER STAGING; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMOSOMAL INSTABILITY; COLITIS; COLITIS ASSOCIATED NEOPLASIA; COLORECTAL CANCER; CPG ISLAND; DISEASE DURATION; DISEASE SEVERITY; DNA DAMAGE; ENTERITIS; GENETIC SUSCEPTIBILITY; GENOMIC INSTABILITY; HETEROZYGOSITY LOSS; HISTOLOGY; HUMAN; IMMUNOTHERAPY; LOSS OF FUNCTION MUTATION; LYMPHOCYTE DIFFERENTIATION; METASTASIS; MICROSATELLITE INSTABILITY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

COLITIS, ULCERATIVE; COLORECTAL NEOPLASMS; CROHN DISEASE; HUMANS; IMMUNOTHERAPY; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-6; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84860185140     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.12.15     Document Type: Review

References (82)

1. Crohn B, Rosenberg H. The sigmoidoscopic picture of chronic ulcerative colitis (non-specific). Am. J. Med. Sci. 170, 220-228 (1925).
2. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48(4), 526-535 (2001). (Pubitemid 32234798)
3. Canavan C, Abrams KR, Mayberry J. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment. Pharmacol. Ther. 23 (8), 1097-1104 (2006). (Pubitemid 43779348)
4. Sachar DB. Cancer in CD: dispelling the myths. Gut 35(11), 1507-1508 (1994).
5. Gillen CD, Walmsley RS, Prior P, Andrews HA, Allan RN. Ulcerative colitis and CD: a comparison of the colorectal cancer risk in extensive colitis. Gut 35(11), 1590-1592 (1994). (Pubitemid 24339258)
6. Itzkowitz SH, Harpaz N. Diagnosis and management of dysplasia in patients with infammatory bowel diseases. Gastroenterology 126(6), 1634-1648 (2004). (Pubitemid 38649879)
7. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J. Clin. 60(5), 277-300 (2 010).
8. Vogelstein B, Fearon ER, Hamilton SR et al. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 319 (9), 525-532 (1988).
9. Winawer SJ, Zauber AG, Ho MN et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Work group. N. Engl. J. Med. 329(27), 1977-1981 (1993). (Pubitemid 24015040)
10. Citarda F, Tomaselli G, Capocaccia R, Barcherini S, Crespi M. Effcacy in standard clinical practice of colonoscopic polypectomy in reducing colorectal cancer incidence. Gut 48 (6), 812-815 (2001). (Pubitemid 32476984)
11. Lieberman D. Progress and challenges in colorectal cancer screening and surveillance. Gastroenterology 138 (6), 2115-2126 (2010).
12. Ullman TA, Itzkowitz SH. Intestinal infammation and cancer. Gastroenterology 140 (6), 1807-1816 (2011).
13. van Schaik FD, Offerhaus GJ, Schipper ME, Siersema PD, Vleggaar FP, Oldenburg B. Endoscopic and pathological aspects of colitis-associated dysplasia. Nat. Rev. Gastroenterol. Hepatol. 6(11), 671-678 (2009).
14. Bernstein CN, Shanahan F, Weinstein WM. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? Lancet 343(8889), 71-74 (1994). (Pubitemid 24019346)
15. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 100(1), 57-70 (2000). (Pubitemid 30046295)
16. Pritchard CC, Grady WM. Colorectal cancer molecular biology moves into clinical practice. Gut 60(1), 116-129 (2011).
17. Grady WM, Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 135(4), 1079-1099 (20 08).
18. Powell SM, Zilz N, Beazer-Barclay Y et al. APC mutations occur early during colorectal tumorigenesis. Nature 359 (6392), 235-237 (1992).
19. Popat S, Houlston RS. A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis. Eur. J. Cancer 41(14), 2060-2070 (2005). (Pubitemid 41337947)
20. Goel GA, Kandiel A, Achkar JP, Lashner B. Molecular pathways underlying IBD-associated colorectal neoplasia: therapeutic implications. Am. J. Gastroenterol. 106 (4), 719-730 (2011).
21. Burmer GC, Rabinovitch PS, Haggitt RC et al. Neoplastic progression in ulcerative colitis: histology, DNA content, and loss of a p53 allele. Gastroenterology 103 (5), 1602-1610 (1992).
22. Itzkowitz SH. Molecular biology of dysplasia and cancer in infammatory bowel disease. Gastroenterol. Clin. N. Am. 35(3), 553-571 (2006). (Pubitemid 44307575)
23. Aust DE, Terdiman JP, Willenbucher RF et al. The APC/b-catenin pathway in ulcerative colitis-related colorectal carcinomas: a mutational analysis. Cancer 94 (5), 1421-1427 (2002). (Pubitemid 34212635)
24. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144 (5), 646-674 (2011).
25. Hussain SP, Harris CC. Infammation and cancer: an ancient link with novel potentials. Int. J. Cancer 121(11), 2373-2380 (2007). (Pubitemid 350022405)
26. Podolsky DK. Infammatory bowel disease. N. Engl. J. Med. 347(6), 417-429 (2002).
27. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of infammatory bowel disease. Nature 448(7152), 427-434 (2007). (Pubitemid 47123518)
28. Sartor RB. Mechanisms of disease: pathogenesis of CD and ulcerative colitis. Nat. Clin. Pract. Gastroenterol. Hepatol. 3(7), 390-407 (2006). (Pubitemid 44018812)
29. Lees C W, Barrett JC, Parkes M, Satsangi J. New IBD genetics: common pathways with other diseases. Gut 60(12), 1739-1753 (2011).
30. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 4(1), 71-78 (2004). (Pubitemid 38082155)
31. Jackson AL, Loeb LA. The contribution of endogenous sources of DNA damage to the multiple mutations in cancer. Mutat. Res. 477(1-2), 7-21 (2001). (Pubitemid 32480184)
32. D'Inca R, Cardin R, Benazzato L, Angriman I, Martines D, Sturniolo GC. Oxidative DNA damage in the mucosa of ulcerative colitis increases with disease duration and dysplasia. Infamm. Bowel Dis. 10(1), 23-27 (2004). (Pubitemid 38072441)
33. Gushima M, Hirahashi M, Matsumoto T et al. Altered expression of MUTYH and an increase in 8-hydroxydeoxyguanosine are early events in ulcerative colitis-associated carcinogenesis. J. Pathol. 219(1), 77-86 (2009).
34. Rachmilewitz D, Stamler JS, Bachwich D, Karmeli F, Ackerman Z, Podolsky DK. Enhanced colonic nitric oxide generation and nitric oxide synthase activity in ulcerative colitis and CD. Gut 36(5), 718-723 (1995).
35. Hussain SP, Amstad P, Raja K et al. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic infammatory disease. Cancer Res. 60(13), 3333-3337 (2000). (Pubitemid 30482141)
36. Roessner A, Kuester D, Malfertheiner P, Schneider-Stock R. Oxidative stress in ulcerative colitis-associated carcinogenesis. Pathol. Res. Pract. 204(7), 511-524 (2008).
37. Gasparini G, Longo R, Sarmiento R, Morabito A. Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? Lancet Oncol. 4(10), 605-615 (2003). (Pubitemid 37258402)
38. Dannenberg AJ, Altorki NK, Boyle JO et al. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol. 2(9), 544-551 (2001). (Pubitemid 33586867)
39. Markowitz SD. Aspirin and colon cancer-targeting prevention? N. Engl. J. Med. 356(21), 2195-2198 (20 07).
40. Singer II, Kawka DW, Schloemann S, Tessner T, Riehl T, Stenson WF. Cyclooxygenase 2 is induced in colonic epithelial cells in infammatory bowel disease. Gastroenterology 115(2), 297-306 (1998). (Pubitemid 28363422)
41. Agoff SN, Brentnall TA, Crispin DA et al. The role of cyclooxygenase 2 in ulcerative colitis-associated neoplasia. Am. J. Pathol. 157(3), 737-745 (2000). (Pubitemid 32109366)
42. Takeda J, Kitajima K, Fujii S et al. Inhibitory effects of etodolac, a selective COX-2 inhibitor, on the occurrence of tumors in colitis-induced tumorigenesis model in rats. Oncol. Rep. 11 (5), 981-985 (2004).
43. Kohno H, Suzuki R, Sugie S, Tanaka T. Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPA R liga nds. BMC Cancer 5, 46 (2005).
44. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl Acad. Sci. USA 72(9), 3666-3670 (1975).
45. Holtmann MH, Neurath MF. Differential TNF-signaling in chronic infammatory disorders. Curr. Mol. Med. 4(4), 439-444 (2004). (Pubitemid 38787012)
46. Hsu H, Xiong J, Goeddel DV. The TNF receptor 1-associated protein TRADD signals cell death and NF-kB activation. Cell 81(4), 495-504 (1995).
47. Hsu H, Shu HB, Pan MG, Goeddel DV. TRADD-TRAF2 and TRADD-FADD interactions defne two distinct TNF receptor 1 signal transduction pathways. Cell 84(2), 299-308 (1996). (Pubitemid 26042835)
48. Braegger CP, Nicholls S, Murch SH, Stephens S, Macdonald TT. Tumour necrosis factor a in stool as a marker of intestinal infammation. Lancet 339 (8785), 89-91 (1992).
49. Murch SH, Lamkin VA, Savage MO, Walker-Smith JA, Macdonald TT. Serum concentrations of tumour necrosis factor a in childhood chronic infammatory bowel disease. Gut 32(8), 913-917 (1991).
50. Van Dullemen HM, Van Deventer SJ, Hommes DW et al. Treatment of CD with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109(1), 129-135 (1995).
51. Popivanova BK, Kitamura K, Wu Y et al. Blocking TNF-a in mice reduces colorectal carcinogenesis associated with chronic colitis. J. Clin. Invest. 118(2), 560-570 (2008). (Pubitemid 351206546)
52. Greten FR, Eckmann L, Greten TF et al. IKKb links infammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118(3), 285-296 (2004). (Pubitemid 39061110)
53. Hirano T, Yasukawa K, Harada H et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 324(6092), 73-76 (1986). (Pubitemid 16008419)
54. Nishimoto N, Kishimoto T Interleukin 6: from bench to bedside. Nat. Clin. Pract. Rheumatol. 2(11), 619-626 (2006).
55. Rose-John S, Scheller J, Elson G, Jones SA. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in infammation and cancer. J. Leukoc. Biol. 80(2), 227-236 (2006). (Pubitemid 44835496)
56. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 374(Pt 1), 1-20 (2003). (Pubitemid 37046923)
57. Neurath MF, Finotto S. IL-6 signaling in autoimmunity, chronic infammation and infammation-associated cancer. Cytokine Growth Factor Rev. 22(2), 83-89 (2011).
58. Gross V, Andus T, Caesar I, Roth M, Scholmerich J. Evidence for continuous stimulation of interleukin-6 production in CD. Gastroenterology 102(2), 514-519 (1992).
59. Mitsuyama K, Sata M, Tanikawa K. Signifcance of interleukin-6 in patients with infammatory bowel disease. Gastroenterol. JPN 26(1), 20-28 (1991).
60. Yamamoto M, Yoshizaki K, Kishimoto T, Ito H. IL-6 is required for the development of Th1 cell-mediated murine colitis. J. Immunol. 164(9), 4878-4882 (2000). (Pubitemid 30238092)
61. Ito H, Takazoe M, Fukuda Y et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 126(4), 989-996, discussion 947 (2004). (Pubitemid 38451170)
62. Chung YC, Chang YF. Serum interleukin-6 levels refect the disease status of colorectal cancer. J. Surg. Oncol. 83(4), 222-226 (2003).
63. Schneider MR, Hoefich A, Fischer JR, Wolf E, Sordat B, Lahm H. Interleukin-6 stimulates clonogenic growth of primary and metastatic human colon carcinoma cells. Cancer Lett. 151(1), 31-38 (2000). (Pubitemid 30155582)
64. Becker C, Fantini MC, Schramm C et al. TGF-b suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 21(4), 491-501 (2004). (Pubitemid 39370505)
65. Grivennikov S, Karin E, Terzic J et al. IL-6 and STAT3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15(2), 103-113 (20 09).
66. Bollrath J, Phesse TJ, Von Burstin VA et al. gp130-mediated STAT3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 15(2), 91-102 (2009).
67. Waldner MJ, Wirtz S, Jefremow A et al. VEGF receptor signaling links infammation and tumorigenesis in colitis-associated cancer. J. Exp. Med. 207(13), 2855-2868 (2010).
68. Bouma G, Strober W. The immunological and genetic basis of infammatory bowel disease. Nat. Rev. Immunol. 3(7), 521-533 (2003). (Pubitemid 37328672)
69. + lamina propria (LP) lymphokine secretion profiles in infammatory bowel disease. CD LP cells manifest increased secretion of IFN-g, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J. Immunol. 157(3), 1261-1270 (1996). (Pubitemid 126449643)
70. Strasly M, Cavallo F, Geuna M et al. IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk. J. Immunol. 166 (6), 3890-3899 (2001). (Pubitemid 32224915)
71. Verbik DJ, Stinson WW, Brunda MJ, Kessinger A, Joshi SS. In vivo therapeutic effects of interleukin-12 against highly metastatic residual lymphoma. Clin. Exp. Metastasis 14(3), 219-229 (1996). (Pubitemid 26246567)
72. Nastala CL, Edington HD, McKinney TG et al. Recombinant IL-12 administration induces tumor regression in association with IFN-g production. J. Immunol. 153(4), 1697-1706 (1994). (Pubitemid 24251114)
73. Brunda MJ, Luistro L, Warrier RR et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med. 178(4), 1223-1230 (1993). (Pubitemid 23277355)
74. Osawa E, Nakajima A, Fujisawa T et al. Predominant T helper type 2-infammatory responses promote murine colon cancers. Int. J. Cancer 118(9), 2232-2236 (2006).
75. Sarra M, Pallone F, Macdonald TT, Monteleone G. IL-23/IL-17 axis in IBD. Infamm. Bowel Dis. 16(10), 1808-1813 (2010).
76. Langowski JL, Zhang X, Wu L et al. IL-23 promotes tumour incidence and growth. Nature 442(7101), 461-465 (2006). (Pubitemid 44264796)
77. Wilke CM, Kryczek I, Wei S et al. Th17 cells in cancer: help or hindrance? Carcinogenesis 32(5), 643-649 (2011).
78. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am. J. Gastroenterol. 100(6), 1345-1353 (2005). (Pubitemid 40904360)
79. Terdiman JP, Steinbuch M, Blumentals WA, Ullman TA, Rubin DT 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with infammatory bowel disease. Infamm. Bowel Dis. 13(4), 367-371 (2007). (Pubitemid 46668239)
80. Eaden J, Abrams K, Ekbom A, Jackson E, Mayberry J. Colorectal cancer prevention in ulcerative colitis: a case-control study Aliment. Pharmacol. Ther. 14(2), 145-153 (2000). (Pubitemid 30088290)
81. Van Staa TP, Card T, Logan RF, Leufkens HG. 5-Aminosalicylate use and colorectal cancer risk in infammatory bowel disease: a large epidemiological study Gut 54(11), 1573-1578 (2005). (Pubitemid 41531774)
82. Rutgeerts P, Sandborn WJ, Feagan BG et al. Infiximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 353(23), 2462-2476 (2005). (Pubitemid 41770166)